Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study

Introduction: A twice-daily single inhaler triple therapy consisting of budesonide/glycopyrrolate/formoterol fumarate (BGF) was approved by the US Food and Drug Administration (FDA) in July 2020 as a maintenance treatment for patients with chronic obstructive pulmonary disease (COPD). The objective...

Full description

Bibliographic Details

Published in:	Therapeutic Advances in Respiratory Disease
Main Authors:	Edward C. Portillo, Michael Pollack, Inyoung Lee, Kainan Sun, Xiaohui Zhao, Lisa Kruse, Norbert Feigler, Sushma Patel, Aimee M. Near
Format:	Article
Language:	English
Published:	SAGE Publishing 2023-04-01
Online Access:	https://doi.org/10.1177/17534666231164534